Utilization and effectiveness of elbasvir/grazoprevir (EBR/GZR) in treatment naïve (TN) genotype 1a (G1A) chronic hepatitis C virus (HCV) patients with/without baseline NS5A resistance-associated substitutions (RASS)

Category Primary study
JournalHepatology
Year 2017
This article has no abstract
Epistemonikos ID: 9f9f6354648a80be9c5c180228e328e7826f271a
First added on: Feb 08, 2025